Guan Qingdong, Zhang Jiguo
Institute of Pharmacology, Taishan Medical University, Tai'an, Shandong Province 271016, China.
Mediators Inflamm. 2017;2017:4810258. doi: 10.1155/2017/4810258. Epub 2017 Mar 21.
Cytokines play an important role in the immunopathogenesis of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, where they drive and regulate multiple aspects of intestinal inflammation. The imbalance between proinflammatory and anti-inflammatory cytokines that occurs in IBD results in disease progression and tissue damage and limits the resolution of inflammation. Targeting cytokines have been novel strategies in the treatment of IBD. Recent studies show the beneficial effects of anticytokine treatments to IBD patients, and multiple novel cytokines are found to be involved in the pathogenesis of IBD. In this review, we will discuss the recent advances of novel biologics in clinics and clinical trials, and novel proinflammatory and anti-inflammatory cytokines found in IBD with focusing on IL-12 family and IL-1 family members as well as their relevance to the potential therapy of IBD.
细胞因子在炎症性肠病(IBD)的免疫发病机制中发挥着重要作用,IBD包括克罗恩病和溃疡性结肠炎,细胞因子在其中驱动和调节肠道炎症的多个方面。IBD中促炎细胞因子和抗炎细胞因子之间的失衡会导致疾病进展和组织损伤,并限制炎症的消退。靶向细胞因子一直是IBD治疗的新策略。最近的研究显示了抗细胞因子治疗对IBD患者的有益效果,并且发现多种新型细胞因子参与了IBD的发病机制。在这篇综述中,我们将讨论新型生物制剂在临床和临床试验中的最新进展,以及在IBD中发现的新型促炎和抗炎细胞因子,重点关注白细胞介素-12家族和白细胞介素-1家族成员,以及它们与IBD潜在治疗的相关性。